C G M Kallenberg - JoVE Visualize

Showing results (11-20 of 71) with videos related to

Pageof 8

Sort By:

Kidney & Blood Pressure Research|September 25, 2003

The Th1 and Th2 paradigm in ANCA-associated vasculitisJ S F Sanders, C A Stegeman, C G M Kallenberg

Molecular Psychiatry|June 26, 2002

Is Tourette's syndrome an autoimmune disease?P J Hoekstra, C G M Kallenberg, J Korf, et al.

Clinical and Experimental Immunology|August 24, 2004

B cell epitope specificity in ANCA-associated vasculitis: does it matter?Y M van der Geld, C A Stegeman, C G M Kallenberg

Annals of the Rheumatic Diseases|May 16, 2007

Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patientsE Reefman, H Kuiper, P C Limburg, et al.

Annals of the Rheumatic Diseases|May 28, 2005

Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complementM Bijl, E Reefman, G Horst, et al.

Annals of the Rheumatic Diseases|May 22, 2003

Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at riskM Bijl, G Horst, H Bootsma, et al.

Autoimmunity Reviews|June 16, 2010

HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions developmentD A Abdulahad, J Westra, P C Limburg, et al.

Rheumatology (Oxford, England)|January 10, 2006

Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatmentJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.

Annals of the Rheumatic Diseases|March 1, 2006

Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapseJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.

Nephron. Clinical Practice|November 18, 2014

Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis and potential targets for biologic treatmentJ S F Sanders, W H Abdulahad, C A Stegeman, et al.

Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:

Pageof 8

Kidney & Blood Pressure Research|September 25, 2003

The Th1 and Th2 paradigm in ANCA-associated vasculitisJ S F Sanders, C A Stegeman, C G M Kallenberg

Molecular Psychiatry|June 26, 2002

Is Tourette's syndrome an autoimmune disease?P J Hoekstra, C G M Kallenberg, J Korf, et al.

Clinical and Experimental Immunology|August 24, 2004

B cell epitope specificity in ANCA-associated vasculitis: does it matter?Y M van der Geld, C A Stegeman, C G M Kallenberg

Annals of the Rheumatic Diseases|May 16, 2007

Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patientsE Reefman, H Kuiper, P C Limburg, et al.

Annals of the Rheumatic Diseases|May 28, 2005

Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complementM Bijl, E Reefman, G Horst, et al.

Annals of the Rheumatic Diseases|May 22, 2003

Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at riskM Bijl, G Horst, H Bootsma, et al.

Autoimmunity Reviews|June 16, 2010

HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions developmentD A Abdulahad, J Westra, P C Limburg, et al.

Rheumatology (Oxford, England)|January 10, 2006

Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatmentJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.

Annals of the Rheumatic Diseases|March 1, 2006

Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapseJ-S F Sanders, M G Huitma, C G M Kallenberg, et al.

Nephron. Clinical Practice|November 18, 2014

Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis and potential targets for biologic treatmentJ S F Sanders, W H Abdulahad, C A Stegeman, et al.

Pageof 8